Business Description
ImmuPharma plc is a UK-based biopharmaceutical company founded in 1999 and headquartered in London, focused on developing peptide-based treatments for autoimmune, inflammatory, and infectious diseases. Its primary asset is P140, a peptide platform currently in late-stage clinical trials for lupus and other conditions including asthma, gout, and bowel disease. The company also has two pre-clinical drugs in development targeting serious fungal infections and bacterial resistance. ImmuPharma works alongside research and commercial partners, including France's Centre National de la Recherche Scientifique and US-based Avion Pharmaceuticals LLC.
